pioglitazone has been researched along with Addiction, Opioid in 3 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "During this investigation, nondependent prescription opioid abusers (N=17 completers) were maintained for 2-3weeks on ascending daily doses of PIO (0mg, 15mg, 45mg) prior to completing a laboratory session assessing the aforementioned effects of OXY [using a within-session cumulative dosing procedure (0, 10, and 20mg, cumulative dose=30mg)]." | 2.82 | The effects of pioglitazone, a PPARĪ³ receptor agonist, on the abuse liability of oxycodone among nondependent opioid users. ( Ciccocioppo, R; Comer, SD; Jones, JD; Manubay, JM; Metz, VE; Mogali, S; Sullivan, MA, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schroeder, JR | 1 |
| Phillips, KA | 1 |
| Epstein, DH | 1 |
| Jobes, ML | 1 |
| Furnari, MA | 1 |
| Kennedy, AP | 1 |
| Heilig, M | 1 |
| Preston, KL | 1 |
| Jones, JD | 1 |
| Sullivan, MA | 1 |
| Manubay, JM | 1 |
| Mogali, S | 1 |
| Metz, VE | 1 |
| Ciccocioppo, R | 2 |
| Comer, SD | 1 |
| de Guglielmo, G | 1 |
| Kallupi, M | 1 |
| Scuppa, G | 1 |
| Demopulos, G | 1 |
| Gaitanaris, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pioglitazone as an Aid During Buprenorphine Taper[NCT01517165] | Phase 1 | 24 participants (Actual) | Interventional | 2012-01-04 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for pioglitazone and Addiction, Opioid
| Article | Year |
|---|---|
Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Cytokines; Double-Blind Method; Female; Humans; Male; Midd | 2018 |
The effects of pioglitazone, a PPARĪ³ receptor agonist, on the abuse liability of oxycodone among nondependent opioid users.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Male; Opioid-Related Disorders; Oxycodone; | 2016 |
1 other study available for pioglitazone and Addiction, Opioid
| Article | Year |
|---|---|
Pioglitazone attenuates the opioid withdrawal and vulnerability to relapse to heroin seeking in rodents.
Topics: Analgesics, Opioid; Animals; Behavior, Addictive; Conditioning, Operant; Heroin; Male; Mice; Morphin | 2017 |